← Back to Search

Virus Therapy

agenT-797 for Respiratory Distress Syndrome

Phase 1 & 2
Waitlist Available
Research Sponsored by MiNK Therapeutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline through month 6
Awards & highlights

Study Summary

This trial is testing a new drug to treat severe lung infections caused by coronavirus and flu.

Eligible Conditions
  • Respiratory Distress Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline through month 6
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline through month 6 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number Of Participants With Dose-limiting Toxicities
Number Of Participants With Treatment-emergent Adverse Events
Secondary outcome measures
Change From Baseline In C-reactive Protein
Decay In Quantitative Viral Burden From Upper And Lower Respiratory Tract Samples
Mean Daily Sequential Organ Failure Assessment Score
+3 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Dosage and CohortsExperimental Treatment1 Intervention
Cohort 1: 100 × 10^6 iNKT cells; Cohort 2: 300 × 10^6 iNKT cells; Cohorts 3 to 4: 1000 × 10^6 iNKT cells Dosage Frequency and Mode of Administration: agenT-797 will be administered to hospitalized participants as a single intravenous infusion.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
agenT-797
2021
Completed Phase 2
~40

Find a Location

Who is running the clinical trial?

MiNK TherapeuticsLead Sponsor
2 Previous Clinical Trials
43 Total Patients Enrolled
Medical DirectorStudy DirectorMiNK Therapeutics
2,777 Previous Clinical Trials
8,063,868 Total Patients Enrolled
1 Trials studying Respiratory Distress Syndrome
40 Patients Enrolled for Respiratory Distress Syndrome

Media Library

agenT-797 (Virus Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04582201 — Phase 1 & 2
Respiratory Distress Syndrome Research Study Groups: Dosage and Cohorts
Respiratory Distress Syndrome Clinical Trial 2023: agenT-797 Highlights & Side Effects. Trial Name: NCT04582201 — Phase 1 & 2
agenT-797 (Virus Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04582201 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Evaluate the Safety of agenT-797 in Participants With Moderate to Severe Difficulty Breathing Secondary to SARS-CoV-2
2020. "Evaluate the Safety of agenT-797 in Participants With Moderate to Severe Difficulty Breathing Secondary to SARS-CoV-2". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04582201.
~4 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top